Bindu Donovan has been litigating high-stakes intellectual property disputes in the life sciences field for over 25 years.

Bindu, a seasoned partner in Morrison Foerster's Intellectual Property Litigation group specializes in patent litigation in U.S. federal district courts. She has a broad range of experience in life sciences, representing clients in matters related to biologic and small-molecule drugs, medical devices, recombinant proteins, and vaccines. Her extensive portfolio extends to representing innovator companies in Hatch-Waxman cases covering treatments for ADHD, diabetes, influenza, hypertension, and metastatic prostate cancer, including blockbuster drugs.

Bindu excels in leading large litigation teams in all aspects of complex patent infringement disputes, including pre-suit investigations, pre-trial and expert discovery, trial preparation, and trial. She is adept at coordinating global strategies for her clients' most important products. Additionally, her experience includes breach of contract and trade secret disputes.

Bindu has been consistently recognized as a leading practitioner in her field. LMG Life Sciences acknowledged her contributions to life sciences-related patent work, and IAM Patent 1000 ranked her as a Leading IP Litigation Lawyer. Additional notable accolades include being named one of the Top 250 Women in Litigation and a Local Litigation Star by Benchmark Litigation. Managing Intellectual Property also named her an “IP Star” and one of the Top 250 Women in IP.

Bindu served as the 2025 President of the New Jersey Intellectual Property Law Association (NJIPLA) and participates in various other legal organizations.

Representative Experience

• Represented an international biopharmaceutical company in patent infringement suit filed under the Hatch-Waxman Act involving a medication for multiple sclerosis.
• Represented international biopharmaceutical company in matter involving offensive and defensive patent assertion strategy concerning vaccines.
• Represented international biopharmaceutical companies in matters involving biologic therapies.
• Represented VMI Holland BV in breach of contract action.
• Represented patent holder Johnson & Johnson subsidiary, Actelion Pharmaceuticals Ltd., in patent infringement suits filed under the Hatch-Waxman Act involving pulmonary arterial hypertension drug Tracleer®.
• Represented patent holder Avanos in patent infringement suit involving cooled radiofrequency ablation products.
• Represented patent holder Johnson & Johnson subsidiary, Janssen, in patent infringement suits filed under the Hatch-Waxman Act and inter partes review proceedings involving prostate cancer drug, Zytiga®.
•  Represented patent holders Gilead and Roche/Genentech in patent infringement suit filed under the Hatch-Waxman Act involving influenza drug, Tamiflu®.
• Represented patent holders Cordis Corporation and Wyeth in patent infringement suits involving drug eluting stents.
• Represented defendant Johnson & Johnson in patent infringement suit involving sunscreen compositions.
• Represented an international biopharmaceutical company in a patent infringement lawsuit filed under the Hatch-Waxman Act involving a medication for ADHD.
• Represented patent holder SmithKline Beecham in patent infringement suit filed under the Hatch-Waxman Act involving Type 2 diabetes drug, Avandia®.